Human Immunodeficiency Virus (HIV) Reagents

Research-grade reagents for Human Immunodeficiency Virus (HIV) — a lentivirus that targets CD4⁺ T cells and causes acquired immunodeficiency syndrome (AIDS), remaining a major global public health challenge. The trimeric envelope glycoprotein complex (gp120/gp41) is the primary target for broadly neutralizing antibodies (bnAbs) and vaccine design, while structural (Gag p24/p17) and accessory/regulatory proteins (Vif, Rev, Nef, Tat) are critical for viral replication and immune evasion. We offer recombinant antibodies & nanobodies (VHH), reference antibodies (research biosimilars), InVivoMAb functional-grade antibodies, polyclonal antibodies, and recombinant proteins covering HIV-1, HIV-2, and SIV targets — validated for ELISA, Western blot, neutralization, flow cytometry, and functional blocking assays. Comprehensive target coverage across Env (gp120, gp41, gp140, gp160), Gag (p24, p17), accessory proteins (Vif, Rev, Nef, Tat), viral enzymes (protease, integrase), and the host co-receptor CCR5 supports vaccine immunogenicity benchmarking, bnAb discovery, HIV cure research, serodiagnostic assay development, and non-human primate model studies. RUO
研究级试剂用于人类免疫缺陷病毒（HIV）——一种针对 CD4 ⁺ T 细胞并引发获得性免疫缺陷综合征（AIDS）的慢病毒，仍是全球重大公共卫生挑战。三聚体包膜糖蛋白复合体（gp120/gp41）是广泛中和抗体（bnAbs）和疫苗设计的主要靶点，而结构性蛋白（Gag p24/p17）和辅助/调控蛋白（Vif、Rev、Nef、Tat）则对病毒复制和免疫逃避至关重要。我们提供重组抗体和纳米抗体（VHH）、参考抗体（研究生物类似药）、InVivoMAb 功能级抗体、多克隆抗体以及覆盖 HIV-1、HIV-2 和 SIV 靶点的重组蛋白 ——均已通过 ELISA 检测、Western blot、中和、流式细胞术和功能阻断检测验证。涵盖 Env（gp120、gp41、gp140、gp160）、Gag（p24、p17）、辅助蛋白（Vif、Rev、Nef、Tat）、病毒酶（蛋白酶、整合酶）及宿主共受体 CCR5 的综合靶点覆盖，支持疫苗免疫原性基准测试、bnAb 发现、HIV 治愈研究、血清诊断检测开发及非人灵长类模型研究。若

Recombinant Antibodies 重组抗体 Broadly neutralizing and detection-grade clones targeting Env (gp120, gp41, gp160) and Gag (p24, p17). Includes well-characterized bnAbs (2G12, IgG1b12, 10E8#) for neutralization assay development, vaccine immunogenicity benchmarking, and epitope mapping studies.
广泛中和和检测级克隆，针对环境（gp120、gp41、gp160）和 Gag（第 24 页，第 17 页）。包括经过充分鉴定的 bnAbs（2G12、IgG1b12、10E8#），用于中和测定开发、疫苗免疫原性基准测试及表位定位研究。

Recombinant Nanobodies (VHH)
重组纳米抗体（VHH） Single-domain antibodies targeting HIV-1 gp120, Gag polyprotein/p17, p24 capsid, and — uniquely — accessory and regulatory proteins Vif, Rev, and Nef. The small size (~15 kDa) of VHH enables intracellular targeting, epitope access in sterically hindered regions, and potential intrabody applications for mechanistic studies of HIV latency and immune evasion.
靶向 HIV-1 gp120、Gag 多蛋白/p17、p24 衣壳，以及独特性地辅助和调控蛋白 Vif、Rev 和 Nef 的单结构域抗体。VHH 体积小（~15 kDa）使得细胞内靶向、在空间受阻区域的表位访问，以及潜在的体内应用，用于 HIV 潜伏和免疫逃避的机制研究。

Reference Antibodies (Research Biosimilars)
参考抗体（研究生物类似药） Research-grade analogs of clinical-stage broadly neutralizing antibodies and HIV entry inhibitors, including anti-gp120 bnAbs (VRC01, Teropavimab, Elipovimab, N6LS, Zinlirvimab, Lafuvitug), anti-gp41 (10E8#), bispecific gp120×CD3 constructs (Amtabafusp Alfa, GS-8588), and anti-CCR5 therapeutics (Leronlimab). Suitable for mechanism-of-action studies, competitive binding assays, and as benchmarking standards in bnAb discovery programs.
临床阶段广泛中和抗体和 HIV 进入抑制剂的研究级类似物，包括抗 gp120 bnAbs（VRC01、特罗帕维单抗、Elipovimab、N6LS、Zinlirvimab、Lafuvitug）、抗 gp41（10E8#）、双特异性 gp120×CD3 构造物（Amtabafusp Alfa，GS-8588）和抗 CCR5 治疗药物（Leronlimab）。适用于作用机制研究、竞争性结合测定以及作为 bnab 发现项目中的基准标准。

InVivoMAb Functional-Grade
InVivoMAb 功能级 Low-endotoxin, azide-free antibodies targeting HIV-1 Env (gp120, gp140 trimer), HIV-2 gp125, and HIV-1 protease. Includes broadly neutralizing clones validated for in vivo neutralization, passive immunization, viral reservoir studies, and protection models in HIV cure and prevention research.
针对 HIV-1 Env（gp120，gp140 三聚体）、HIV-2 gp125 和 HIV-1 蛋白酶的低内毒素、无叠氮化物抗体。包括广泛中和克隆体，已验证体内中和、被动免疫、病毒储存基研究及 HIV 治愈与预防保护模型。

Polyclonal Antibodies 多克隆抗体 Broad-spectrum detection reagents for HIV-1 (gp120, p24, Tat), HIV-2 (gp36/Env), and SIV (gp120, Gag, Integrase, VIF, VPX, Nef) proteins. Validated for Western blot confirmation, immunoprecipitation, and cross-species detection in non-human primate (NHP) model systems essential for preclinical vaccine and therapeutic studies.
针对 HIV-1（gp120、p24、Tat）、HIV-2（gp36/Env）和 SIV（gp120、Gag、Integrase、VIF、VPX、Nef）蛋白的广谱检测试剂。已验证用于非人灵长类动物（NHP）模型系统中的西方印迹确认、免疫沉淀及跨物种检测，这些对临床前疫苗和治疗研究至关重要。

Recombinant Proteins 重组蛋白 His-tagged, GST-tagged, and SUMO-tagged viral antigens covering HIV-1 Env (gp120, gp140), Gag (p24), Tat, HIV-2 Env (gp120, gp36), and a comprehensive SIV panel (gp120, Gag, Integrase, VIF, VPX, Nef). Validated for SDS-PAGE and Western blot. Suitable as coating antigens for serodiagnostic ELISA development, immunogens for antibody generation, and reference standards for vaccine potency and serological surveillance assays.
其标记、GST 标记和 SUMO 标记的病毒抗原，涵盖 HIV-1 Env（gp120、gp140）、Gag（p24）、Tat、HIV-2Env（gp120、gp36）及综合 SIV 面板（gp120、Gag、Integrase、VIF、VPX、Nef）。已通过 SDS-PAGE 和西方印迹验证。适合作为血清诊断 ELISA 开发的包覆抗原、抗体生成的免疫原，以及疫苗效力和血清学监测检测的参考标准。

All products manufactured by AtaGenix Laboratories under ISO 9001 & ISO 13485 quality systems.
所有产品均由 AtaGenix Laboratories 在 ISO 9001 和 ISO 13485 质量体系下制造。

References 参考文献

1. Kwong PD, Mascola JR, Nabel GJ. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol. 2013;13(9):693-701. DOI

2. Sok D, Burton DR. Recent progress in broadly neutralizing antibodies to HIV. Nat Immunol. 2018;19(11):1179-1188. DOI

3. Frankel AD, Young JA. HIV-1: fifteen proteins and an RNA. Annu Rev Biochem. 1998;67:1-25. DOI

4. Mouquet H. Antibody B cell responses in HIV-1 infection. Trends Immunol. 2014;35(11):549-561. DOI